» Articles » PMID: 19634191

Making and Circumventing Tolerance to Cancer

Overview
Journal Eur J Immunol
Date 2009 Jul 28
PMID 19634191
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The interactions between cancer and immune cells are complex. Even though the mutations that cause cancer can create new antigens that are potentially "visible" to T cells, in most experimental model systems the growth of tumors is accompanied by induction of T-cell tolerance towards the tumor. How tolerance to tumors is induced and how tolerance can be broken by immunotherapy have been a main focus in cancer immunology. Here, we discuss experimental models used in cancer immunology. We argue that, while it is obviously easy for tumors to induce tolerance, it should be as easy to circumvent tolerance by the adoptive transfer of tumor-antigen-reactive T cells. Effective adoptive T-cell therapy has become feasible by methods to identify TCR against tumor-associated (self-) antigens with high affinity and to graft a new antigen specificity to patients' T cells by TCR gene transfer.

Citing Articles

The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.

Hedlund G, Eriksson H, Sundstedt A, Forsberg G, Jakobsen B, Pumphrey N PLoS One. 2013; 8(10):e79082.

PMID: 24194959 PMC: 3806850. DOI: 10.1371/journal.pone.0079082.


Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery.

Fu X, Rivera A, Tao L, Zhang X Int J Cancer. 2013; 133(10):2483-92.

PMID: 23661285 PMC: 3770832. DOI: 10.1002/ijc.28269.


A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Fiorenza S, Kenna T, Comerford I, McColl S, Steptoe R, Leggatt G J Immunol. 2012; 189(12):5622-31.

PMID: 23144496 PMC: 3518562. DOI: 10.4049/jimmunol.1200709.


MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.

Soto C, Stone J, Chervin A, Engels B, Schreiber H, Roy E Cancer Immunol Immunother. 2012; 62(2):359-69.

PMID: 22926060 PMC: 3570684. DOI: 10.1007/s00262-012-1336-z.


Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.

Marr L, Gilham D, Campbell J, Fraser A Clin Exp Immunol. 2012; 167(2):216-25.

PMID: 22235997 PMC: 3278687. DOI: 10.1111/j.1365-2249.2011.04517.x.